Foundayo for Weight Loss
Eli Lilly's daily weight loss pill, FDA approved April 2026. The first GLP-1 pill that does not require an empty stomach, a 30-minute wait, or a specific time of day.
Reviewed by GlobalGLP1 editorial team • Last reviewed March 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Foundayo is a once-daily pill from Eli Lilly that was FDA approved in April 2026 for chronic weight management. It is the first GLP-1 medication available as a regular small-molecule tablet, which means it works at any time of day with or without food or water. The active ingredient is orforglipron. In the ATTAIN-1 Phase 3 trial, people on the highest FDA-approved dose lost an average of 12.4% of their body weight over 72 weeks. That is less than injectable Wegovy or Zepbound, but for people who cannot tolerate needles, travel often, or have run into injection supply shortages, the pill format is a real change. Foundayo is approved for adults with obesity (BMI 30 or higher) or with overweight (BMI 27+) plus a weight-related health condition like high blood pressure, type 2 diabetes, or sleep apnea.
How Foundayo Works
Foundayo is the brand name for orforglipron. It works by activating the GLP-1 receptor, the same hunger pathway that Wegovy and Ozempic target with injections. The difference is that Foundayo is a small-molecule drug, so it absorbs reliably as a pill and does not need an empty stomach, a 30-minute wait, or a specific time of day. You take one tablet daily, with or without food or water, whenever fits your routine.
FDA Approval
Foundayo
Chronic weight management in adults
0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg once-daily tablets (escalating dose; 17.2 mg is the maintenance dose)
How You Take It
The full build-up takes a few months. Picking a consistent time each day helps you remember, but skipping a window does not require special timing the way Rybelsus does.
How Much Weight You Can Lose
In the ATTAIN-1 Phase 3 trial, people on the 17.2 mg maintenance dose lost an average of 12.4% of their body weight over 72 weeks, compared to 0.9% with placebo. The FDA label reports average weight loss of 7.4% to 11.1% across the lower approved tablet doses. For a 200-pound person on the highest dose, 12.4% is roughly 25 pounds.
Side Effects
Common Side Effects
- Nausea (most common during dose increases, usually eases over a few weeks)
- Constipation (common, often helped by fluids and fiber)
- Diarrhea (typically mild and short-lived)
- Vomiting (most common in the first weeks, drops off after the first month)
- Indigestion and heartburn (mild for most people)
- Abdominal pain (usually mild)
- Headache
- Belching and gas
- Fatigue (often improves as your body adjusts)
- Hair thinning (reported by some patients, usually temporary)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, observed in rodents)
- Acute kidney injury (linked to dehydration from severe vomiting or diarrhea)
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Allergic reactions
Managing side effects: Stomach side effects are most common during the first weeks and around each dose increase, then ease as your body adjusts. The slow build-up exists for this reason. Eat smaller meals, stay hydrated (especially important with Foundayo because dehydration from GI side effects can hurt the kidneys), and avoid greasy or very rich foods. If nausea is bad enough that you cannot keep fluids down, contact your provider. They can slow or pause the dose escalation.
Foundayo Cost & Savings (2026)
Savings programs: Foundayo Savings Card: commercially insured patients may pay as little as $25 per month if their plan covers Foundayo. Lilly Cares Patient Assistance Program may cover Foundayo for free for qualifying uninsured patients who meet income limits. Medicare and Medicaid patients are not eligible for the commercial savings card.
Who Should Not Take Foundayo
- Personal or family history of medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to orforglipron or any ingredient in Foundayo
- Pregnancy or planning to become pregnant
- History of inflamed pancreas (pancreatitis), use with caution
- Severe stomach or intestinal disease (gastroparesis)
What to Expect, Month by Month
Most patients notice decreased hunger and smaller portion sizes. Some early nausea is common.
Measurable weight loss begins as the dose escalates to 14.5 mg. Average 2-4% body weight lost during escalation.
On the full 17.2 mg dose. Steady weight loss of about 1 pound per week. GI side effects have usually settled.
Average 8-12% body weight lost. Blood pressure, cholesterol, and blood sugar improvements measurable.
Weight loss plateau near 12.4% average. Maintenance phase begins.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will usually reduce your insulin or sulfonylurea dose when starting Foundayo.
Foundayo slows digestion, which can change how other oral medications absorb. Less of an issue than with injected GLP-1s because the effect is milder, but tell your prescriber about every drug you take.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting Foundayo or changing your dose.
Birth control pills should still work normally, but consider backup contraception during the first few weeks if you are concerned, especially during dose increases.
Special Situations
Do not use during pregnancy. Stop Foundayo well before trying to conceive. Animal studies showed harm to the fetus.
Use with caution. Foundayo carries a specific warning about acute kidney injury linked to dehydration from severe vomiting or diarrhea. Stay well hydrated, especially during dose increases.
No dose change needed for mild to moderate liver issues. Limited data in severe liver disease.
A subgroup analysis of ATTAIN-1 and ATTAIN-2 showed adults 65 and older lost up to 13% of body weight with Foundayo. No dose change needed, but watch for dehydration since GI side effects can hit older adults harder.
Not currently FDA-approved for adolescents. Studies in younger populations are planned.
What Happens If You Stop
Like other GLP-1 medications, weight tends to come back when you stop. Trial data suggests Foundayo behaves similarly to other GLP-1s on this front: most patients regain a significant portion of lost weight within a year of stopping if they do not maintain diet and exercise changes.
How to make stopping easier: Build sustainable eating and movement habits while on the medication so you have a foundation when you stop. Some patients transition to a lower maintenance dose long-term, which is easier and cheaper with a daily pill than with weekly injections. Talk with your prescriber before stopping suddenly.
Foundayo FAQs
Foundayo is a daily pill version of a GLP-1 medication. Wegovy and Zepbound are weekly injections. Foundayo produces less weight loss on average (~12.4% vs ~15% for Wegovy and ~22.5% for Zepbound), but it removes the needle, refrigeration, and weekly-shot routine entirely. For people who cannot tolerate injections, travel a lot, or want a simpler routine, Foundayo is the first real alternative.
Both are GLP-1 pills, but they work differently. Rybelsus is an oral version of injected semaglutide, a peptide, which means it has to be taken on an empty stomach with no food, drink, or other medications for at least 30 minutes after. Foundayo is a small-molecule drug, so it can be taken any time of day, with or without food or water. Foundayo also produced more weight loss in trials.
List price is roughly $700 to $1,000 per month at retail pharmacies. Eli Lilly may roll out a direct-pay option through LillyDirect at a discount once supply stabilizes. Most people will pay less with insurance and the Foundayo Savings Card.
In the ATTAIN-1 trial, people on the 17.2 mg maintenance dose lost an average of 12.4% of their body weight over 72 weeks, compared to 0.9% with placebo. Across the lower approved tablet doses, the FDA label reports average weight loss of 7.4% to 11.1%. Results vary depending on dose, diet, exercise, and how your body responds.
Coverage is rolling out through 2026 as commercial plans update their formularies. Many will cover Foundayo with prior authorization, requiring a BMI of 30 or higher (or 27+ with a weight-related condition). Medicare does not cover GLP-1s for weight loss alone, but coverage may expand for patients with obesity and cardiovascular disease. Medicaid coverage varies by state.
Any licensed doctor or nurse practitioner can prescribe it. In-person and telehealth clinics that prescribe other GLP-1s will typically prescribe Foundayo as well. Use the directory below to find providers in your state.
Nausea, constipation, diarrhea, vomiting, and abdominal pain are the most common. They tend to be worst during the first few weeks and around dose increases. A small number of patients report temporary hair thinning. Severe vomiting or diarrhea can cause dehydration, so contact your provider if you cannot keep fluids down. Foundayo carries the same boxed warning about thyroid C-cell tumors as other GLP-1s, based on rodent studies.
Looking for a Clinic?
Foundayo is a new medication. While our directory does not yet have confirmed Foundayo prescribers, many GLP-1 clinics will prescribe it for eligible patients.
Browse GLP-1 Clinics →Related Foundayo resources
Looking for Foundayo?
Foundayo is a new medication. Our directory does not yet have confirmed Foundayo prescribers, but many of our 3,323 GLP-1 clinics will prescribe it for eligible patients. Browse all clinics or ask any GLP-1 prescriber about availability.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.